Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 136 AL 150

An acetylation-phosphorylation switch that regulates tau aggregation propensity and function

Carlomagno Y, Chung DC, Yue M, Castanedes-Casey M, Madden BJ, Dunmore J, Tong J, DeTure M, Dickson DW, Petrucelli L, Cook C.

J Biol Chem. 2017 Sep 15;292(37):15277-15286. doi: 10.1074/jbc.M117.794602. Epub 2017 Jul 31.

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease

Lee JK, Kim NJ.

Molecules. 2017 Aug 2;22(8):1287. doi: 10.3390/molecules22081287.

MicroRNA Dysregulation in Alzheimer's Disease

Putteeraj M, Fairuz YM, Teoh SL.

CNS Neurol Disord Drug Targets. 2017;16(9):1000-1009. doi: 10.2174/1871527316666170807142311.

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents

Jouanne M, Rault S, Voisin-Chiret AS.

Eur J Med Chem. 2017 Oct 20;139:153-167. doi: 10.1016/j.ejmech.2017.07.070. Epub 2017 Jul 29.

Human induced pluripotent stem cells as a research tool in Alzheimer's disease

Robbins JP, Price J.

Psychol Med. 2017 Nov;47(15):2587-2592. doi: 10.1017/S0033291717002124. Epub 2017 Aug 14.

Effect of Chinese Herbal Medicine on Alzheimer's Disease

Howes MR, Fang R, Houghton PJ.

Int Rev Neurobiol. 2017;135:29-56. doi: 10.1016/bs.irn.2017.02.003. Epub 2017 Mar 24.

Curcumin in Alzheimer's disease: Can we think to new strategies and perspectives for this molecule?

Serafini MM, Catanzaro M, Rosini M, Racchi M, Lanni C.

Pharmacol Res. 2017 Oct;124:146-155. doi: 10.1016/j.phrs.2017.08.004. Epub 2017 Aug 12.

Resveratrol for Alzheimer's disease

Sawda C, Moussa C, Turner RS.

Ann N Y Acad Sci. 2017 Sep;1403(1):142-149. doi: 10.1111/nyas.13431. Epub 2017 Aug 16.

Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease

Moussa CE.

Expert Opin Investig Drugs. 2017 Oct;26(10):1131-1136. doi: 10.1080/13543784.2017.1369527. Epub 2017 Aug 23.

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease

Brody DL, Jiang H, Wildburger N, Esparza TJ.

Alzheimers Res Ther. 2017 Aug 17;9(1):62. doi: 10.1186/s13195-017-0293-3.

PSEN1 gene polymorphisms in Caucasian Alzheimer's disease: A meta-analysis

Ramakrishnan V, Akram Husain RS, Ahmed SSSJ.

Clin Chim Acta. 2017 Oct;473:65-70. doi: 10.1016/j.cca.2017.08.016. Epub 2017 Aug 15.

Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis

Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, Chou KR.

PLoS One. 2017 Aug 21;12(8):e0183586. doi: 10.1371/journal.pone.0183586. eCollection 2017.

Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease

Kou X, Chen N.

Nutrients. 2017 Aug 24;9(9):927. doi: 10.3390/nu9090927.

Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors

Arafa RK, Elghazawy NH.

Adv Exp Med Biol. 2017;1007:199-224. doi: 10.1007/978-3-319-60733-7_11.

AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease

Glynn-Servedio BE, Ranola TS.

Consult Pharm. 2017 Sep 1;32(9):511-518. doi: 10.4140/TCP.n.2017.511.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias